Cyto-immuno-therapy for Cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocells

Vista sencilla de ítem
dc.contributor.authorSagnella, Sharon M.
dc.contributor.authorYang, Lu
dc.contributor.authorStubbs, Gemma E.
dc.contributor.authorBoslem, Ebru
dc.contributor.authorMartino-Echarri, Estefania
dc.contributor.authorSmolarczyk, Katarzyna
dc.contributor.authorPattison, Stacey L.
dc.contributor.authorVanegas, Natasha
dc.contributor.authorSt Clair, Eva
dc.contributor.authorClarke, Stephen
dc.contributor.authorBoockvar, John
dc.contributor.authorMacDiarmid, Jennifer A.
dc.contributor.authorBrahmbhatt, Himanshu
dc.date.accessioned2022-10-31T15:40:07Z
dc.date.available2022-10-31T15:40:07Z
dc.date.issued2020
dc.description.abstractenglishImmunotherapy has emerged as a powerful new chapter in the fight against cancer. However, it has yet to reach its full potential due in part to the complexity of the cancer immune response. We demonstrate that tumor-targeting EDV nanocells function as an immunotherapeutic by delivering a cytotoxin in conjunction with activation of the immune system. These nanocells polarize M1 macrophages and activate NK cells concurrently producing a Th1 cytokine response resulting in potent antitumor function. Dendritic cell maturation and antigen presentation follows, which generates tumor-specific CD8+ T cells, conferring prolonged tumor remission. The combination of cytotoxin delivery and activation of innate and adaptive antitumor immune responses results in a potent cyto-immunotherapeutic with potential in clinical oncology.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.ccell.2020.02.001
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1878-3686
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/9250
dc.language.isoeng
dc.publisherCellPressspa
dc.publisher.journalCancer Cellspa
dc.relation.ispartofseriesCancer Cell, 1878-3686, Vol. 37, No. 03, 2020, p. 354-370spa
dc.relation.urihttps://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30090-8
dc.rights.accessrightshttps://purl.org/coar/access_right/c_14cb
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccess
dc.rights.accessrightsAcceso cerrado
dc.subjectCáncerspa
dc.subjectTerapia combinadaspa
dc.subjectCitoinmunoterapiaspa
dc.subjectInmunoterapiaspa
dc.subjectNanocélulasspa
dc.subjectSupercitotoxinaspa
dc.subjectObjetivo del tumorspa
dc.subject.keywordsPNU-159682spa
dc.subject.keywordsCancerspa
dc.subject.keywordsCombined therapeuticspa
dc.subject.keywordsCyto-immunotherapyspa
dc.subject.keywordsImmunotherapyspa
dc.subject.keywordsNanocellspa
dc.subject.keywordsSupercytotoxinspa
dc.subject.keywordsTumor targetingspa
dc.titleCyto-immuno-therapy for Cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocellsspa
dc.title.translatedCyto-immuno-therapy for Cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocellsspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Sagnella_Sharon_M._2020.pdf
Tamaño:
4.38 MB
Formato:
Adobe Portable Document Format
Descripción:
Cyto-immuno-therapy for Cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocells
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos